Iktos
Quentin Perron has a diverse and extensive work experience in the fields of data science and artificial intelligence. Quentin is currently serving as the Co-Founder and CSO of Iktos, a French start-up company that specializes in developing innovative AI technology for drug design. At Iktos, Quentin is responsible for leading the company's deep learning models and algorithm development.
Prior to their role at Iktos, Quentin worked as an Advisory Director of Data Science at Publicis ETO between April 2016 and August 2017. Quentin provided valuable insights and guidance in the field of data science for the company.
Quentin also served as a Senior Data Scientist at Quinten from December 2013 to March 2016. During this time, they conducted data science consulting projects, machine learning, and data visualization. Additionally, they provided expertise in medicinal chemistry, agrochemistry, cosmetics, and industrial processes.
Before joining Quinten, Quentin worked as a Research Scientist at Servier from May 2012 to October 2013. Quentin also gained research experience as a Post-Doc at UCLA from December 2010 to December 2011. Furthermore, they received training in the pharmaceutical industry at Novartis in 2006 and at Technion - Israel Institute of Technology in 2005.
Overall, Quentin Perron's work experience highlights their expertise in artificial intelligence, data science, drug design, and research, making him a valuable asset in the field.
Quentin Perron earned their undergraduate degree in Organic Chemistry from ENSCCF in 2006. Quentin then pursued further education and completed their PhD in Organometallic Chemistry from the University of Geneva (UNIGE) in 2010. Afterward, they undertook a post-doctoral research position at UCLA in California, United States of America from 2010 to 2011, focusing on Total Synthesis.
This person is not in any offices
Iktos
Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.